Payment overview · 2025
General Payments
$783.10
16 reported records · 9 companies
Healthcare provider profile · identity verified
Astrid Gutsmann, DO, PH.D.
Allopathic & Osteopathic Physicians|Family Medicine · ALLEN, TX · NPI 1003851676
Verified facts
What the public records show
CMS Open Payments records show Astrid Gutsmann, DO, PH.D. received $783.10 in general payments during 2025 across 16 reported records.
Abbott Laboratories accounted for 32.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $251.56 | 32.1% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $155.76 | 19.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $121.86 | 15.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $120.68 | 15.4% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $48.63 | 6.2% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.40 | 3.2% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.16 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.09 | 2.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.96 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $783.10 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $251.56 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $155.76 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $121.86 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $120.68 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $48.63 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $25.40 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
70 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 530 | 153 |
| Atorvastatin Calcium | Atorvastatin Calcium | 461 | 141 |
| Amlodipine Besylate | Amlodipine Besylate | 300 | 98 |
| Lisinopril | Lisinopril | 220 | 72 |
| Metformin Hcl | Metformin Hcl | 217 | 67 |
| Alprazolam | Alprazolam | 161 | 31 |
| Gabapentin | Gabapentin | 142 | 42 |
| Losartan Potassium | Losartan Potassium | 141 | 44 |
| Sertraline Hcl | Sertraline Hcl | 138 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 134 | 38 |
| Montelukast Sodium | Montelukast Sodium | 125 | 41 |
| Simvastatin | Simvastatin | 119 | 36 |
| Ezetimibe | Ezetimibe | 108 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 106 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 28 |
| Trazodone Hcl | Trazodone Hcl | 98 | 31 |
| Metformin Hcl Er | Metformin Hcl | 97 | 29 |
| Omeprazole | Omeprazole | 97 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 26 |
| Tramadol Hcl | Tramadol Hcl | 95 | 33 |
| Glipizide | Glipizide | 89 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 83 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 21 |
| Ozempic | Semaglutide | 76 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 30 |
| Bupropion Xl | Bupropion Hcl | 72 | 15 |
| Synthroid | Levothyroxine Sodium | 72 | 16 |
| Farxiga | Dapagliflozin Propanediol | 70 | 19 |
| Meloxicam | Meloxicam | 65 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 22 |
| Furosemide | Furosemide | 58 | 20 |
| Temazepam | Temazepam | 58 | 12 |
| Liothyronine Sodium | Liothyronine Sodium | 57 | 20 |
| Progesterone | Progesterone, Micronized | 57 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 17 |
| Carvedilol | Carvedilol | 53 | 15 |
| Celecoxib | Celecoxib | 52 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 52 | 12 |
| Buspirone Hcl | Buspirone Hcl | 51 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 14 |
| Allopurinol | Allopurinol | 44 | 14 |
| Potassium Chloride | Potassium Chloride | 44 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Nateglinide | Nateglinide | 40 | 14 |
| Estradiol | Estradiol | 39 | 16 |
| Eliquis | Apixaban | 37 | suppressed |
| Rybelsus | Semaglutide | 35 | 12 |
| Atenolol | Atenolol | 34 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 27 |
| Estradiol (Twice Weekly) | Estradiol | 32 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | 12 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | suppressed |
| Glipizide Er | Glipizide | 29 | 12 |
| Clonazepam | Clonazepam | 28 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 23 |
| Azithromycin | Azithromycin | 26 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Np Thyroid | Thyroid,pork | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Prednisone | Prednisone | 17 | 14 |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Perindopril Erbumine | Perindopril Erbumine | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Tresiba | Insulin Degludec | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $783.10 · 16 records | Abbott Laboratories | ABRYSVO, COMIRNATY, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, Korlym, PREVNAR 20, Symbravo, Tlando, XYOSTED, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error